BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-150@catalystbrief.girapphe.com
DTSTAMP:20261118T181554Z
LAST-MODIFIED:20261118T181554Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Gilead Sciences — Sacituzumab Govitecan-hziy [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Asian Study of Sacituzumab Goviteca
 n (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC).\nSource: https:/
 /clinicaltrials.gov/study/NCT04639986\nhttps://catalystbrief.girapphe.com/
 e/150?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/150?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
